Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Patients in New York City with cancer who are then diagnosed with novel coronavirus 2019 (COVID-19) are marked by substantial hospitalization rates and severe outcomes.

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Chung-Han Lee, MD, PhD, discusses the potential for combining TKIs with immunotherapy in patients with metastatic renal cell carcinoma who have progressed on prior checkpoint inhibitors.

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Ariela Noy, MD, discusses the rationale and design of the phase 2 study of devimistat in patients with aggressive lymphoma.

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.